Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Travere Therapeutics Inc TVTX

Healthcare Biotechnology
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. Sparsentan is also in late-stage development for... see more

Recent & Breaking News (NDAQ:TVTX)

Retrophin to Report First Quarter 2017 Financial Results

GlobeNewswire April 20, 2017

Retrophin Appoints Ron Squarer to Board of Directors

GlobeNewswire April 12, 2017

John A. Orwin Joins Retrophin Board of Directors

GlobeNewswire March 23, 2017

Retrophin to Present at the Barclays Global Healthcare Conference

GlobeNewswire March 7, 2017

Retrophin Provides Sparsentan Regulatory Update; Reports Fourth Quarter and Full Year 2016 Financial Results

GlobeNewswire March 1, 2017

Retrophin to Report Fourth Quarter and Full Year 2016 Financial Results

GlobeNewswire February 15, 2017

Retrophin Appoints William Rote Senior Vice President, Research and Development

GlobeNewswire February 13, 2017

Healthcare Stocks Under Scanner -- Aerie Pharma, GW Pharma, Retrophin, and SciClone Pharma

PR Newswire February 9, 2017

Retrophin Provides Corporate Update and 2017 Preview

GlobeNewswire January 9, 2017

Retrophin Appoints Elizabeth Reed General Counsel

GlobeNewswire January 4, 2017

Research Reports Initiation on Drug Makers Stocks -- Aerie Pharma, Impax Laboratories, Retrophin, and GW Pharma

PR Newswire December 30, 2016

Retrophin to Present at the 35th Annual J.P. Morgan Healthcare Conference

GlobeNewswire December 29, 2016

JMP Conducts Retrophin Survey To Understand Story

Benzinga.com  December 15, 2016

Retrophin to Present at the BMO Capital Markets Healthcare Conference

GlobeNewswire November 30, 2016

Retrophin Reports Additional Positive Data from Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis at ASN Kidney Week 2016

GlobeNewswire November 19, 2016

Technical Reports on Drug Makers Equities -- Impax Labs, Retrophin, Heron Therapeutics, and GW Pharma

PR Newswire November 17, 2016

Retrophin Reaches Agreement with FDA under Special Protocol Assessment for Pivotal Trial Evaluating RE-024 in PKAN

GlobeNewswire November 10, 2016

Retrophin Reports Third Quarter 2016 Financial Results

GlobeNewswire November 3, 2016

Retrophin to Present Additional Data from Phase 2 DUET Study of Sparsentan in Late-Breaking Oral Session at ASN Kidney Week 2016

GlobeNewswire October 21, 2016

Retrophin to Report Third Quarter 2016 Financial Results

GlobeNewswire October 20, 2016